FMR1 premutation and full mutation molecular mechanisms related to autism. by Hagerman, Randi et al.
UC Davis
UC Davis Previously Published Works
Title
FMR1 premutation and full mutation molecular mechanisms related to autism.
Permalink
https://escholarship.org/uc/item/66x6j4kn
Journal
Journal of neurodevelopmental disorders, 3(3)
ISSN
1866-1947
Authors
Hagerman, Randi
Au, Jacky
Hagerman, Paul
Publication Date
2011-09-01
DOI
10.1007/s11689-011-9084-5
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
FMR1 premutation and full mutation molecular
mechanisms related to autism
Randi Hagerman & Jacky Au & Paul Hagerman
Received: 29 November 2010 /Accepted: 9 May 2011 /Published online: 27 May 2011
# Springer Science+Business Media, LLC 2011
Abstract Fragile X syndrome (FXS) is caused by an
expanded CGG repeat (>200 repeats) in the 5′ un-translated
portion of the fragile X mental retardation 1 gene (FMR1)
leading to a deficiency or absence of the FMR1 protein
(FMRP). FMRP is an RNA-binding protein that regulates
the translation of a number of other genes that are important
for synaptic development and plasticity. Furthermore, many
of these genes, when mutated, have been linked to autism
in the general population, which may explain the high
comorbidity that exists between FXS and autism spectrum
disorders (ASD). Additionally, premutation repeat expan-
sions (55 to 200 CGG repeats) may also give rise to ASD
through a different molecular mechanism that involves a
direct toxic effect of FMR1 mRNA. It is believed that RNA
toxicity underlies much of the premutation-related involve-
ment, including developmental concerns like autism, as
well as neurodegenerative issues with aging such as the
fragile X-associated tremor ataxia syndrome (FXTAS).
RNA toxicity can also lead to mitochondrial dysfunction,
which is common in older premutation carriers both with
and without FXTAS. Many of the problems with cellular
dysregulation in both premutation and full mutation
neurons also parallel the cellular abnormalities that have
been documented in idiopathic autism. Research regarding
dysregulation of neurotransmitter systems caused by the
lack of FMRP in FXS, including metabotropic glutamate
receptor 1/5 (mGluR1/5) pathway and GABA pathways,
has led to new targeted treatments for FXS. Preliminary
evidence suggests that these new targeted treatments will
also be beneficial in non-fragile X forms of autism.
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Introduction
The fragile X mental retardation 1 (FMR1) gene gives rise
to a family of disorders when its non-coding CGG-repeat
element is expanded to either the premutation range (55–
200 CGG repeats) or the full mutation range (>200 CGG
repeats). Although most individuals with the premutation
have normal intellectual abilities, some children with the
premutation have developmental problems including atten-
tion deficit hyperactivity disorder (ADHD), shyness, social
anxiety, and autism spectrum disorders (ASD; Farzin et al.
2006; Aziz et al. 2003; Clifford et al. 2007), although the
incidence of each of these problems is awaiting further
studies of unbiased populations of carriers. The premutation
is also associated with adult-onset disorders, including the
fragile X-associated tremor/ataxia syndrome (FXTAS) in
both males and females (males 40%; females 16%) over
age 50 and fragile X-associated primary ovarian insuffi-
R. Hagerman
Department of Pediatrics, University of California, Davis,
School of Medicine,
Sacramento, CA, USA
R. Hagerman (*) : J. Au
MIND Institute, University of California, Davis, Health System,
2825 50th street,
Sacramento 95817 CA, USA
e-mail: Randi.hagerman@ucdmc.ucdavis.edu
P. Hagerman
Department of Biochemistry and Molecular Medicine,
University of California, Davis, School of Medicine,
Davis, CA, USA
J Neurodevelop Disord (2011) 3:211–224
DOI 10.1007/s11689-011-9084-5
ciency (FXPOI) in approximately 20% of female carriers
under 40 years. The premutation is relatively common in
the general population, present in approximately 1 in 130 to
250 women and 1 in 250 to 810 males (Fernandez-Carvajal
et al. 2009; Hagerman 2008; Song et al. 2003; Dombrowski
et al. 2002). The full mutation is less common at
approximately 1 per 2,500 to 1 per 4,000 (Fernandez-
Carvajal et al. 2009; Hagerman 2008; Coffee et al. 2009).
Those with a full mutation, which gives rise to fragile X
syndrome (FXS), are more likely to develop ASD than
those with the premutation and approximately 30% of boys
with FXS have autism and an additional 30% have
pervasive developmental disorder—not otherwise specified
(PDD-NOS) (Harris et al. 2008; Hatton et al. 2006;
Hernandez et al. 2009).
There are two different molecular mechanisms of
involvement leading to pathology in FMR1 mutations.
The full mutation leads to methylation of the gene, causing
a lack of transcription and translation and resulting in an
absence or deficiency of FMR1 protein (FMRP). FMRP is
an RNA-binding and transport protein that also regulates
the translation of many messages that are important for
synaptic plasticity, neuronal migration, and adult neuro-
genesis (Bassell and Warren 2008; Zalfa et al. 2007;
Darnell et al. 2005, 2010; Luo et al. 2010; Miyashiro et al.
2003). In stark contrast, the premutation allele produces
elevated levels of FMR1 mRNA (Tassone et al. 2000a;
Kenneson et al. 2001; Peprah et al. 2010), leading to an
RNA toxic gain of function that is associated with
disruption of the nuclear lamin A/C architecture, a
significant stress response in both neuronal and non-
neural cells, and dysregulation of a variety of proteins
(Iwahashi et al. 2006; Sellier et al. 2010a, b; Garcia-
Arocena and Hagerman 2010). In addition, recent reports
have documented deficits of FMRP in some brain regions
of premutation mice (Qin et al. 2011) and also in the blood
of some carriers particularly in the upper premutation
range (Peprah et al. 2010). Therefore, some of the
premutation involvement may also be due to lowered
FMRP levels.
Autism is a behaviorally defined disorder (DSM IV TR
criteria) that arises through one or more of a large number
of genetic and/or environmental factors. Mutations in
numerous recognized genes are known to be highly
associated with autism, operating through mechanisms that
alter/disrupt critical functions, including synaptic plasticity,
the balance of inhibitory and excitatory pathways, regula-
tion of mammalian target of rapamycin (mTOR) pathways,
mitochondrial function, immune function, and neuronal
migration (Nishimura et al. 2007; Belmonte and Bourgeron
2006; de Vries 2010; Wegiel et al. 2010; Ashwood et al.
2009; Giulivi et al. 2010; Betancur et al. 2009; Rubenstein
and Merzenich 2003; Gogolla et al. 2009; Gatto and
Broadie 2010). Furthermore, premutation and full mutation
alleles have overlapping involvement for many of these
molecular mechanisms that can lead to autism or ASD
(Gatto and Broadie 2010; Hagerman et al. 2010; D"Hulst et
al. 2009; D"Hulst and Kooy 2007; Gibson et al. 2008). The
mechanistic linkage between autism and FXS underscores
the seminal role of FMRP as an mRNA transporter and as a
regulator of translation predominantly through inhibition of
the many messages that are critical for synaptic maturation
and synaptic plasticity (De Rubeis and Bagni 2010; Napoli
et al. 2008; Muddashetty et al. 2007). In this regard, the
lack of FMRP leads to dramatic upregulation of protein
production in the CNS (Qin et al. 2005) and upregulation of
the metabotropic glutamate receptor 5 (mGluR5) pathway
(Huber et al. 2002; Krueger and Bear 2011) and down-
regulation of the GABAA pathways (D"Hulst et al. 2009;
D"Hulst and Kooy 2007). This imbalance between the
glutamate and GABA systems can also be seen in autism
(Rubenstein and Merzenich 2003; Belmonte et al. 2004) in
the context of other mutations associated with autism not
associated with FXS (Betancur et al. 2009; Gogolla et al.
2009; Abrahams and Geschwind 2008). This coupling
between FXS and autism suggests that the development of
new targeted treatments for FXS, including the use of
mGluR5 antagonists (Wang et al. 2010), or GABA agonists
may turn out to be helpful for autism and other disorders
that do not have an FMR1 mutation, but which do have
similar GABA and glutamate imbalances (Wang et al.
2010).
Clinical features of fragile X syndrome
FXS usually presents in the first 2 years of life, with
developmental delays in language and with hypotonia.
Some children have difficulty coordinating a suck in the
newborn period and frequent emesis is common. Physical
features in childhood include prominent ears and hyper-
extensible finger joints. Macroorchidism (large testicles)
typically does not develop until early puberty (Hagerman
2002). Tactile defensiveness, avoidance of eye contact, and
hyperactivity usually develop by age 2 and are associated
with hyperarousal to sensory stimuli. This hyperarousal can
lead to tantrums and irritability, or mood lability in addition
to anxiety (Hagerman 2002; Cordeiro et al. 2011; Sullivan
et al. 2006; Budimirovic et al. 2006). The presence of
autistic-like features, such as hand flapping, perseveration
in behavior and language, avoidance of eye contact, and
avoidance of light touch, spurred further research on the
relationship between FXS and autism. However, detailed
studies have demonstrated that it is the severity of the social
and language deficits which leads to the diagnosis of autism
in about 30% of boys with FXS (Kaufmann et al. 2004;
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Lewis et al. 2006), with another 30% meeting criteria for
PDD-NOS (Harris et al. 2008). Roberts et al. (2007) have
demonstrated that most patients with FXS are initially
avoidant of social interactions, but that those with autism
continue to be physically and socially avoidant over time.
In addition, those investigators found that children with
both FXS and autism had higher basal and follow-up
cortisol levels compared with those with FXS without
autism. Lower cognitive and language abilities are also seen
in FXS with autism compared with FXS alone, though the
presence of autism is not driven by FMRP levels (Loesch et
al. 2007; McDuffie et al. 2010).
The occurrence of autism in those with FXS is likely
related to a number of factors that can worsen CNS
function in addition to FXS alone. Garcia-Nonell et al.
(2008) found that those with FXS and autism had a higher
rate of medical problems that affect the CNS, including
seizures and additional genetic disorders, such as Down
syndrome (Stevens et al. 2010) or the Prader–Willi
phenotype (PWP) of FXS (Nowicki et al. 2007). Higher
rates of seizures were also found by Berry-Kravis et al.
(2010a) in those with FXS and autism compared with FXS
alone. The PWP in FXS, first reported by Fryns et al.
(1987), is defined by the presence of hyperphagia, obesity,
lack of satiation, and hypogenitalia. Several subsequent
reports have described this subtype of FXS with severe
obesity; it is suggested that the hypogenitalia and the lack
of satiation after meals represent more severe hypothalamic
dysfunction than what is typically seen in FXS (Fryns et al.
1987; Schrander-Stumpel et al. 1994; de Vries et al. 1993;
de Vries and Niermeijer 1994). Individuals with the PWP
do not have a deletion at 15q11–13, nor do they have
uniparental disomy, but typically have a higher rate of
autism compared with those with FXS alone (Nowicki et al.
2007). In addition, individuals with the PWP have down-
regulation of CYFIP1 (located between breakpoints 1 and 2
in the 15q deletion region associated with Prader–Willi
syndrome) in peripheral blood compared with those with
FXS without the PWP or controls (Nowicki et al. 2007).
The downregulation of CYFIP in the PWP of FXS is likely
to be an epigenetic effect, but the basis for its reduced
expression is unknown. Further study of the role of
background genetic effects and the role of environment in
the development of autism in FXS is needed.
Most boys with FXS are diagnosed with ADHD by the
time they are 5 years old and typically do well with
stimulant medication (Berry-Kravis and Potanos 2003;
Hagerman et al. 1988). Self-injurious behavior is seen in
58% of boys and 17% of girls with FXS, whereas
compulsive behavior is seen in 72% of boys and 55% of
girls (Hall et al. 2008a). The average IQ of an adult male
with FXS is in the 40s, although 15% can present with an
IQ>70% because of mosaicism or a lack of methylation in
the full mutation (Merenstein et al. 1996; Hall et al. 2008b;
Hagerman et al. 1994a). The level of cognitive abilities is
positively correlated to the FMRP level, as are many of the
physical features of FXS, including prominent ears and
hyperextensible finger joints (Loesch et al. 2004). Because
of the close association of a low IQ with autism in FXS,
one would expect that autism would correlate with FMRP
levels, but this is not the case once IQ is controlled for
(Loesch et al. 2007; McDuffie et al. 2010). Autism in FXS
also improves with age, particularly the reciprocal social
communication abilities (Hernandez et al. 2009; McDuffie
et al. 2010) as is seen in idiopathic autism (Seltzer et al.
2003; Shattuck et al. 2007).
Girls with FXS are typically less affected cognitively
than boys due to the additional normal X chromosome that
produces FMRP. Approximately 25% to 33% of girls with
the full mutation have an IQ less than 70, and the majority
have borderline or low normal cognitive abilities (Cordeiro
et al. 2011; Bennetto and Pennington 2002). Executive
function deficits are common even in those with a normal
IQ (Bennetto et al. 2001). Higher functioning women have
a favorable activation ratio (the proportion of cells with the
normal X as the active X), and this correlates with a higher
FMRP level (Tassone et al. 1999). Approximately 15% to
25% of girls with the full mutation have autism or ASD
(Clifford et al. 2007; Cordeiro et al. 2011; Leigh et al.,
unpublished data), and they also tend to improve their
autism over time (McDuffie et al. 2010). Cordeiro et al.
(2011) assessed anxiety disorders in 39 girls with the full
mutation (mean age 12.4 years; range 5.5–33.3 years) using
a standardized psychiatric interview, Anxiety Disorders
Interview Scale for DSM IV, and found that 39% met
criteria for social phobia, 51.4% for specific phobia, 21%
for selective mutism, and 18% for generalized anxiety
disorder. They also found that 25% had ASD, whereas only
2% met criteria for full autism. Although fewer girls with
the full mutation meet autism criteria compared with males,
anxiety disorders are very common and usually respond
well to a selective serotonin reuptake inhibitor (SSRI)
(Hagerman et al. 2009; Berry-Kravis and Potanos 2004;
Amaria et al. 2001; Hagerman et al. 1994b). However, the
data regarding response to an SSRI in patients with FXS is
from surveys in fragile X clinics, and a controlled trial is
needed to demonstrate efficacy.
Molecular aspects of fragile X syndrome
FMRP is an RNA-binding and transport protein that is
associated with the transport and stabilization of mRNAs
(De Rubeis and Bagni 2010). At the synapse, FMRP
regulates the translation of numerous messages (Bassell and
Warren 2008; Levenga et al. 2009, 2010). FMRP binds to a
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number of proteins, including FXR1P, FXR2P, NUFIP,
CYFIP, and kinesin light chain, among others (Dictenberg
et al. 2008; Bardoni et al. 1999; Schenck et al. 2001;
Davidovic et al. 2007), forming an RNP particle. FMRP
suppresses translation of mRNAs at the level of translation
initiation (Napoli et al. 2008). It is thought that the
microRNA (miRNA) pathway and the ribonucleoprotein
RNA-induced silencing complex (RISC) are also part of the
RNPs that contain FMRP. Unphosphorylated FMRP asso-
ciates with Dicer, and this complex processes pre-miRNAs
into mature miRNAs (Cheever and Ceman 2009a, b).
miRNAs are small single-stranded RNAs that are important
for processing mRNA for degradation or translation. In the
nucleus, pri-miRNAs are processed by Drosha, an RNAse
III endonuclease, into pre-miRNA, which are then pro-
cessed into mature miRNAs that also work with RISC.
Edbauer et al. (2010) have shown that FMRP interacts with
miRNA132 and miRNA125b, and this regulates the
translation of NMDA receptor subunit 2A. There is an
enhancement of protein production in the hippocampus by
approximately 20% in the knock out (KO) FXS mouse (Qin
et al. 2005; Dolen et al. 2007).
A number of proteins have been shown to bind to FMRP
and presumably are regulated by FMRP through translation
or stabilization of their messages, including neuroligins 3
and 4, neurorexins, PSD-95, SHANK3, Arc, PTEN,
MAPK, JKMIP, HERC, CYFIP1, and others (Darnell et
al. 2005, 2010; Miyashiro et al. 2003; Nishimura et al.
2007; Levenga et al. 2010; Dahlhaus and El-Husseini
2010). Many of these proteins, when mutated, can cause an
increased risk for autism. Therefore, there is significant
overlap in the dysregulation of protein systems between
various forms of autism and FXS (Betancur et al. 2009;
Hagerman et al. 2010). In addition, Sharma et al. (2010)
have demonstrated the there is upregulation of mTOR in the
KO mouse, which has also been shown to occur in humans
with FXS (Tassone 2010). mTOR is upregulated in other
forms of autism, including tuberous sclerosis and PTEN
mutations; rapamycin is being tested as a targeted treatment
for these disorders (de Vries 2010; Zhou et al. 2009).
Co-immunoprecipitation studies and functional assays
have demonstrated that numerous presynaptic and postsyn-
aptic proteins are regulated by FMRP so that, in the
absence of FMRP, there is significant dysregulation of
synaptic plasticity, which is another reason that there is a
close association between autism and FXS (Darnell et al.
2010; Betancur et al. 2009).
One of the important systems upregulated by the absence
of FMRP is the mGluR5 pathway that leads to long-term
depression (LTD), or weakening of synaptic connections
(Huber et al. 2002; Bear et al. 2004). FMRP normally
inhibits the protein translation that occurs with mGluR5
stimulation, and this protein translation leads to internali-
zation of α-amino-3-hydroxy-5-methyl-4-isoxazolepro-
pionic acid (AMPA) receptors, which weakens synaptic
connections, leading to LTD. In the absence of FMRP, LTD
is enhanced and morphologically, there are long, thin, and
immature dendritic spines in the hippocampus and else-
where in the brain (Irwin et al. 2005). These immature
spines are rescued by crossing the KO mouse with an
mGluR5-deficient mouse so that the offspring have reduced
mGluR5 activity (Dolen et al. 2007). This finding has had
important therapeutic implications for patients with FXS in
that mGluR5 antagonists can reverse the neurobiological
findings of immature dendritic spines, in addition to
epilepsy and behavioral and cognitive abnormalities in
animal models (Levenga et al. 2010; Yan et al. 2005; de
Vrij et al. 2008; McBride et al. 2005; Dolen et al. 2010).
Currently, there are three mGluR5 antagonists that have
been used in human trials: fenobam which was successful
in a single dose in 12 adults with FXS (Berry-Kravis et
al. 2009); AFQ056, developed by Novartis and which has
completed a European trial with positive significant
effects only in those with FXS and methylated FMR1
alleles (Jacquemont et al. 2011) with no significant
response in those without methylation; and R04917523,
developed by Roche and currently in a multicenter
controlled trial in the USA. It is hoped that both
behavioral and cognitive benefits will occur in those with
FXS who are treated with mGluR5 antagonists, but we
have to wait for further studies to understand the impact of
these targeted treatments.
Silverman et al. (2010) studied the autism mouse model
BTBR which has social deficits and repetitive and
restrictive behavior of repetitive self-grooming. The BTBR
mouse was treated with MPEP, an mGluR5 antagonist that
has reversed the fragile X neurobiological abnormalities in
the KO mouse. They found reversal of the repetitive self-
grooming behavior without sedation in the BTBR mouse
with MPEP treatment suggesting that mGluR5 antagonists
may be helpful in those with autism without the FMR1
mutation (Silverman et al. 2010).
Other pathways important for behavior and cognition are
also negatively impacted by the loss of FMRP in FXS. The
GABA system is generally downregulated in the absence of
FMRP (D"Hulst et al. 2009; D"Hulst and Kooy 2007; El
Idrissi et al. 2005), and use of Arbaclofen, a GABAB
agonist, has been both helpful in the KO mouse and most
importantly in children and adults with FXS (Berry-Kravis
et al. 2010b). This medication is the R isomer of Baclofen,
which has been available for years in the treatment of
cerebral palsy. Ganaxolone is a GABAA agonist with
potential utility in FXS since the GABAA receptors are
significantly lowered in the disorder (D"Hulst et al. 2009).
Preliminary studies in the KO mouse have shown positive
effects on behavior (Kooy et al. 2010).
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Recently, Olmos-Serrano et al. (2010) documented
deficits in inhibitory transmission in the amygdala of the
KO mouse including dramatic reduction in the frequency
and amplitude of phasic inhibitory postsynaptic currents, in
tonic inhibitory currents as well as a reduction in the
number of inhibitory synapses. There were significant
alterations in GABA availability both intracellularly and
at the synaptic cleft. This led to hyperexcitability in the
principal neurons of the amygdala which was rescued by
treatment with a GABA agonist, Gaboxadol. This animal
evidence is further support of the need for GABA agonists
in the treatment of patients with FXS. Work by Suvrathan et
al. (2010) in the amygdala of the KO mouse demonstrated
that the mGluR5 antagonist MPEP only rescued the
decrease in the miniature excitatory postsynaptic currents
and MPEP did not rescue the deficit in long-term
potentiation or surface expression of the AMPA receptor
in the amygdala. Therefore, it is likely that combined
psychopharmacologic interventions with targeted treat-
ments will be needed in FXS.
Recently, Bilousova et al. (2009) reported that matrix
metalloproteinase 9 (MMP9), a protein important for
maintenance of synaptic plasticity, was significantly elevat-
ed in the CNS of the KO mouse. The authors demonstrated
that treatment of the neonatal mouse for a 1-month period
with minocycline, which lowers MMP9, led to significant
maturation of the dendritic spines and improvements in
behavior and cognition in the KO mouse. This report
generated much interest in the families of children with
FXS because minocycline is available currently by pre-
scription. However, minocycline used before 8 years of age
can lead to significant graying of the permanent teeth. A
survey of 50 patients with FXS who were treated for longer
than 2 weeks demonstrated that families perceived a
positive effect, particularly in language and behavior, in
70% of patients (Utari et al. 2010). Side effects were
minimal, although one patient had graying of his fingernails
and toenails and another was thought to have graying of the
teeth. Although the positive results of the minocycline trial
were likely influenced by a placebo effect, the appropriate
controlled trial is currently underway to determine whether
this treatment is effective in children (Wang et al. 2010). An
open trial of minocycline reported by Paribello et al. (2010)
in 20 patients with FXS ages 13–32 years demonstrated
benefit in the Aberrant Behavior Checklist, the Clinical
Global Improvement Scale, and the visual analog scale for
behavior with minimal side effects. Recent studies of
minocycline also show enhancement of the EIF4AI
translation factor (Hashimoto and Ishima 2010) which
may be of benefit in patients with FXS. In addition,
minocycline is a neuroprotective agent, and it is highly
effective in blocking or inhibiting cytochrome C release
from mouse liver mitochondria both in vitro and in vivo
(Wang et al. 2008). Screening of 1,040 compounds by the
Neurodegeneration Drug Screening Consortium of NINDS
found that minocycline was the second most effective drug
to block cytochrome C release in response to Ca++
stimulation (Wang et al. 2008). There is significant
oxidative stress in the cells from those with FXS (de
Diego-Otero et al. 2009) in addition to cells from those with
premutation involvement (Ross-Inta et al. 2010) and
idiopathic autism (Giulivi et al. 2010). Therefore, stabiliza-
tion of mitochondria is likely an important issue (and
therapeutic target) across neurodevelopmental, one that
requires further study.
Other potential therapeutic approaches, including the use
of PIK3 inhibitors (Gross et al. 2010), GSK3β antagonists
including lithium (Berry-Kravis et al. 2008), or miRNA
targeting (Muddashetty and Bassell 2009), are also being
considered as therapeutic approaches for FXS. It is likely
that more than one targeted treatment will be needed for the
reversal of both the cognitive and behavioral problems in
those with FXS. Furthermore, the use of enhanced learning
techniques such as computer and assistive technology will
be needed as the synaptic connections are strengthened to
maintain and augment these improvements (Wang et al.
2010).
Involvement in carriers of premutation alleles
There is a broad spectrum of involvement of developmental
and neurological problems with aging that can occur with
the premutation (Fig. 1). For many years, those with the
premutation were thought to be unaffected, except for
FXPOI, which was first reported by Cronister et al. in 1991
(Cronister et al. 1991). Mothers who bring their children
into clinic are usually without apparent clinical involvement
cognitively, although anxiety and depression are common
(Roberts et al. 2009). When the mothers themselves are
carriers of full mutation alleles, learning and emotional
problems are more common than in carriers of premutation
alleles (Bennetto and Pennington 2002).
Males with the premutation were once called normal
transmitting males and therefore, by definition, were
considered normal. However, in 1996, cognitive and
behavioral problems with the premutation were first
reported in three boys who presented with learning
disabilities or ADHD, which were thought to be related to
a mild decrease of FMRP (Hagerman et al. 1996). Reports
of premutation involvement became more common after the
premutation was associated with elevated levels of FMR1
mRNA in 2000 (Tassone et al. 2000a). Elevated mRNA in
the premutation was also confirmed by other groups
(Kenneson et al. 2001; Peprah et al. 2010; Allen et al.
2004). Multiple case reports of premutation involvement,
J Neurodevelop Disord (2011) 3:211–224 215
mainly in males, included reports of autism and ASD
(Farzin et al. 2006; Aziz et al. 2003; Clifford et al. 2007;
Tassone et al. 2000b; Goodlin-Jones et al. 2004); neverthe-
less, only a subgroup of premutation carriers had develop-
mental problems. Specifically, these reports include ten
boys who were assessed for fragile X, including eight who
were tested because of developmental or behavioral prob-
lems and two who were siblings of boys with FXS (Aziz et
al. 2003). Of these ten cases, four had repeats less than 50
CGGs (in the gray zone), three of whom were found to
have ASDs. Of the remaining six, one had Asperger’s
syndrome with a 56 CGG repeat. In the Clifford et al.
(2007) study, there were seven males with the premutation;
two were probands in fragile X families, and one of these
had ASD (14% overall). In the study of Goodlin-Jones et al.
(2004), there were four boys and two girls with ASD and
the premutation, and they were compared with premutation
patients without ASD. Although the CGG repeat number
did not differ between the two groups, the level of FMRP
was significantly lower in the premutation carriers who had
ASD (Goodlin-Jones et al. 2004). These case reports
suggest that those who present clinically with the premu-
tation were more likely to be diagnosed with ASD. The
subsequent study by Farzin et al. (2006) was designed to
test this hypothesis. This study (Farzin et al. 2006) included
14 boys (probands) with the premutation who presented
clinically, 13 boys (nonprobands) with the premutation who
were identified with the premutation through cascade
testing of the family once a proband was diagnosed, and
16 boys who were siblings but did not have the premutation
(controls). After a detailed assessment, utilizing standard-
ized testing to assess ASD and ADHD, it was found that 13
of 14 (93%) of the probands had ADHD, and all were
receiving medication to treat this problem. This was
significantly increased from 6 of 13 (38%) of the non-
probands with ADHD and 2 of 16 (13%) of the controls.
Regarding a diagnosis of ASD, 10 of 14 (71%) of the
probands had an ASD diagnosis compared with 1 of 13
(8%) of the nonprobands and 0 of 16 controls. This study
demonstrates that probands are at higher risk for both
ADHD and ASD, but the overall prevalence of these
problems will require a longitudinal follow-up study of
premutation carriers diagnosed at birth to eliminate any
residual bias. The assessment of more than 1,000 families
by web questionnaires demonstrated a prevalence of autism
or ASD of 13% in boys with the premutation and 1% in
girls with the premutation (Bailey et al. 2008).
It is not known why some children with the premutation
have developmental problems whereas most do not. ASD
and perhaps other developmental problems in premutation
children are more common in boys, and the study of
Goodlin-Jones et al. demonstrated a 50% rate of seizures in
the affected premutation carriers in addition to lowered
FMRP compared with the comparison premutation carriers
without ASD. It is likely that seizures (perhaps related to
lower FMRP) further interfere with brain connectivity in
the vulnerable patient during development, and therefore,
the child would be more likely to develop an autism
spectrum disorder (Brooks-Kayal 2010). Also recent animal
studies of the premutation mouse demonstrate lowered
levels of FMRP in addition to elevated FMR1-mRNA in
many brain areas, particularly the amygdala, hippocampus,
and cortex, when compared with controls without the
premutation (Qin et al. 2011). It is likely that both of these
changes cause significant problems with cognition and
behavior, particularly in those with a premutation over 150
repeats.
There is also evidence that brain connectivity may be
different in some carriers compared with controls in brain
imaging studies. In young adult males with the premutation,
Fig. 1 This depicts the molecu-
lar changes and the spectrum of
clinical involvement in premu-
tation carriers
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there is a deficit of amygdala activation on MRI to fearful
faces compared with their brothers who do not have the
premutation (Hessl et al. 2007). In carriers, amygdala
activation to non-fearful faces was normal compared with
their brothers, suggesting that the deficit may be specific to
emotionally activating stimuli. In addition, a recent fMRI
study by Hashimoto et al. (2010) has demonstrated that
activation of the right ventral inferior frontal cortex and left
premotor/dorsal inferior frontal cortex is significantly
deficient in adult male carriers without neurological disease
compared with age-matched controls. There was a negative
correlation between the right ventral inferior frontal cortex
activation and the level of FMR1-mRNA. The authors
suggest that these alterations in the prefrontal cortex may
underlie both the executive function and memory deficits
that are seen in older carriers, even those without FXTAS.
In MRI studies of gray matter loss, the region of interest
analysis in asymptomatic premutation carriers demonstrated
gray matter loss in the anterior subregions of the cerebellar
vermis compared with age-matched controls (Hashimoto et
al. 2011a). There was a negative effect of the CGG repeat
size on the gray matter density in the dorsomedial frontal
regions in carriers. In addition, diffusion tensor imaging
changes in premutation carriers without neurological prob-
lems compared with age-matched controls demonstrated
elevations in axial diffusivity and redial diffusivity in the
middle cerebellar peduncles (MCP) compared with controls
(Hashimoto et al. 2011b). This area of the MCP becomes
more significantly involved with severe white matter
disease if a carrier develops FXTAS as described below.
Although the imaging studies suggest early subclinical
involvement in the brain of carriers without FXTAS, a large
study by Hunter et al. (2008) did not show neuropsycho-
logical deficits in carriers compared with non-carriers in
those under the age of 50 years. There were 506 women
and 138 men between the ages of 18 to 50 years, but these
numbers included only 30 males with the premutation,
although 298 females had the premutation. There were no
neuropsychological deficits in the males, but in the larger
cohort of females, there were significantly more severe
symptoms associated with ADHD than the non-carrier
females. There was also an association of repeat length
with a factor of self-reported inattention and impulsivity,
suggesting again that the higher the CGG repeat within the
premutation range, the greater the clinical involvement. In
comparing the Hunter study to other centers that have
carried out neuropsychological studies of premutation
carriers, there is a difference perhaps in ascertainment and
in the measures utilized since the other centers have seen
problems in a subgroup of carriers. The Cornish et al.
(2008) found executive function deficits in adult male
carriers that worsened over time from just inattention to
dysinhibition with age. Similar findings were seen by
Moore et al. (2004) and from studies by Grigsby et al.
(2006, 2008) and Brega et al. (2008). Further collaborative
work utilizing sensitive measures to early executive
function deficits should clarify whether carriers are at
greater risk for ADHD and executive function deficits as
they age.
Recent studies of hippocampal neurons with the premu-
tation in culture have demonstrated changes that support the
developmental problems described in children. Chen et al.
(2010) reported that premutation neuronal cultures demon-
strate reduced dendritic complexity with shorter dendritic
lengths and fewer branches between 7 and 21 days in vitro
compared with wild-type (WT) neurons. Synaptic structure
was also different in premutation neurons in that the size of
puncta labeled with synapsin (presynaptic vesicle protein)
and postsynaptic puncta labeled with phalloidin were larger
compared with WT at 14 and 21 days in culture. In
addition, premutation neurons die more easily in culture by
21 days compared with normal neurons, suggesting that
they may be more vulnerable to environmental trauma or
toxicity (Chen et al. 2010). The premutation neurons also
demonstrate elevations of stress proteins and their mRNAs,
including heat shock proteins (Hsp27 and Hsp70) and αB-
crystallin, which have been reported in fibroblasts from
premutation carriers (Garcia-Arocena et al. 2010). These
changes are also consistent with the cellular loss and brain
atrophy seen in patients with FXTAS and with the neuro-
developmental problems reported in some children with the
premutation. Perhaps the neuronal cell loss that was
demonstrated in vitro can be exacerbated by the stress of
seizures, making it more likely for ASD to develop in
premutation carriers with seizures.
Further support for neurodevelopmental problems in the
premutation comes from studies of the migration of
premutation neurons. Cunningham et al. (2010) have
reported altered embryonic neocortical development in the
premutation mouse compared with WT. They found
orientation deficits of migrating neurons and a decrease in
the neural precursor cell marker Tbr2 in these mice. They
also detected a 42% reduction in FMRP levels in the
premutation embryonic telencephalon. The knock-in (KI)
premutation mouse model has also been helpful in detecting
early deficits in learning. By 12 weeks, the premutation
mouse was unable to detect a change in the distance
between two objects, and at 48 weeks, they could not detect
a transposition of objects (Hunsaker et al. 2010).
Premutation alleles can also lead to significant neuro-
toxicity with aging, specifically FXTAS which occurs in
approximately 40% of males and 10–16% of females who
are older than 50 years (Jacquemont et al. 2004; Coffey et
al. 2008; Rodriguez-Revenga et al. 2009). The premutation
also leads to toxicity in the ovary, such that approximately
20% of women with the premutation experience early
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ovarian failure or insufficiency (FXPOI) before age 40
(Sherman et al. 2007; Wittenberger et al. 2007). FXTAS
was first reported in 2001 (Hagerman et al. 2001) with five
case reports of the onset of an intention tremor initially
followed by ataxia and evidence of brain atrophy and white
matter disease on T2 imaging. Further studies documented
involvement of autonomic function including impotence,
hypertension, orthostatic hypotension, and eventually uri-
nary and bowel incontinence, neuropathy symptoms (par-
ticularly pain), parkinsonism, executive function deficits,
cognitive decline with eventual dementia in 50% of people,
and emotional difficulties including irritability, apathy, and
depression (Grigsby et al. 2008; Jacquemont et al. 2003,
2007; Bacalman et al. 2006; Seritan et al. 2008; Berry-
Kravis et al. 2007; Allen et al. 2008; Soontarapornchai et
al. 2008; Aguilar et al. 2008; Leehey et al. 2007). MRI
features include global brain atrophy and white matter
disease with spongiosis involving the MCP sign, periven-
tricular regions, subcortical regions, and pons (Adams et al.
2007, 2010; Cohen et al. 2006; Brunberg et al. 2003).
Females are less affected than males, both radiologically
and cognitively (Coffey et al. 2008; Adams et al. 2007;
Hagerman et al. 2004), but they often have autoimmune
problems including hypothyroidism and fibromyalgia (Coffey
et al. 2008) with the rare occurrence of multiple sclerosis
(Zhang et al. 2009).
Although psychiatric involvement is not seen in the
majority of children with the premutation, psychiatric
symptoms of depression and/or anxiety can occur in mid-
adulthood. A detailed study by Roberts et al. (2009) of 93
women with the premutation demonstrated a mood disorder
in 47%, which was significantly higher than the comparison
group from the National Comorbidity Survey Replication
data set. Similar results were seen in a study of 85
premutation carriers (both men and women), including
lifetime mood disorder in 65% of those with FXTAS and
42% in those without FXTAS and lifetime anxiety disorder
in 52% of those with FXTAS and in 47% of those without
FXTAS (Bourgeois et al. 2011).
The RNA toxicity can involve not only the limbic but
also the endocrine system with either FXTAS, FXPOI, or
other neurological problems (Gokden et al. 2009; Greco et
al. 2007). Impotence is commonly seen before the onset of
tremor and ataxia and inclusions eventually develop in the
Leydig cells of the testicles that produce testosterone
(Greco et al. 2007). The involvement from the premutation
is depicted in Fig. 1, and it is far broader and more common
than involvement from the full mutation. Coffey et al.
(2008) found a higher rate of muscle pain, fibromyalgia,
thyroid disease, neuropathy symptoms, and hypertension in
141 female carriers compared with age-matched controls. A
study by Rodriguez-Revenga et al. (2009) found similar
problems in over 280 female carriers with chronic muscle
pain in 24.4%, thyroid disease in 15.9%, and FXPOI in
18.6%. Hunter et al. (2010) studied 334 women with the
premutation and 37 men with the premutation compared
with controls between the ages of 18–50 years. Men with
the premutation did not report any medical condition at
higher rates than non-carriers. However, women with the
premutation reported mental health disorders including
ADHD, anxiety, and depression significantly more often
that non-carriers, although after adjusting for covariates
these increased rates were not significant. However, women
with ovarian insufficiency, as manifested by irregular
cycles, reported higher rates of thyroid problems and
depression/anxiety compared with controls. Clearly further
studies are warranted regarding the medical, particularly
autoimmune problems, such as thyroid disease and fibro-
myalgia, in carriers compared with controls.
Because the increased rate of autoimmune problems in
parents of children with FXS is similar to what has been
found in parents of children with autism (Atladottir et al.
2009), Chonchaiya et al. (2010) studied the FXS children
(n=61) of mothers who have autoimmune disease com-
pared with the children (n=97) of mothers without
autoimmune disease. The hypothesis was that the children
of mothers with autoimmune disease would be more likely
to have autism. The odds ratio (OR) for ASD was 1.27
which was not significantly different, but the OR for
seizures was 3.81 (p=0.031) and the OR for tics was 2.94
(p=0.019) so they were significantly increased in children
of mothers with autoimmune disease. This suggests that
there is an intergenerational effect of autoimmune disease
in those with the premutation on their offspring, similar to
what has been reported in a subgroup of patients with
autism (Ashwood et al. 2006; Enstrom et al. 2009; Martin
et al. 2008). Ashwood et al. (2010) have also studied the
cytokine and chemokine profile of those with FXS both
with and without autism compared with controls. They
found significant differences in plasma protein levels of a
number of cytokines including increased in IL-1α with a
decrease in the chemokines RANTES and IP-10 between
FXS and typicals. Those with FXS without autism had
higher levels of IL-6, eotaxin, and MCP1α but lowered
levels of RANTES compared with FXS with autism. The
alterations of these profiles are likely to create meaningful
changes in neurodevelopment, and this has been reviewed
in autism (Enstrom et al. 2009).
RNA toxic gain of function as a basis for premutation
disorders
The unique neuropathological finding in FXTAS is the
presence of intranuclear inclusions in neurons and astro-
cytes throughout the brain, particularly in the hippocampus
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and limbic systems (Greco et al. 2002, 2006). These
inclusions are also found in the premutation KI mouse in
both neurons and astrocytes (Wenzel et al. 2010). The
inclusions are tau and synuclein negative but are positive
for FMR1 mRNA. The toxicity of the premutation is
thought to relate to sequestration of important proteins by
the expanded-CGG-repeat mRNA (Sellier et al. 2010b;
Garcia-Arocena and Hagerman 2010). These proteins
include splicing proteins of other RNAs in addition to
Drosha, which regulates miRNAs (Kenneson et al. 2001).
The sequestration may develop slowly over time such that
symptoms of neurodegeneration are not seen until late
adulthood, as is reported with the development of inclu-
sions over time in the premutation mouse (Wenzel et al.
2010; Brouwer et al. 2007).
Most recently, Ross-Inta et al. (2010) demonstrated
mitochondrial dysfunction in fibroblasts and brain samples
in premutation carriers both with and without FXTAS.
Mitochondrial dysfunction in carriers included uncoupling
between electron transport and synthesis of ATP in addition
to decreased levels of mitochondrial proteins such as the
ATPase β-subunit from complex V, cytochrome c oxidase
subunit IV from complex IV, and MnSOD as part of the
mitochondrial antioxidant defense. These findings were
most severe in those with FXTAS, but they were also
present in carriers without FXTAS. Patients with FXTAS
gradually become very weak as their disease progresses,
which is consistent with a worsening of mitochondrial
function. What is not known is whether young children
with the premutation, particularly those who are affected
with an ASD, also demonstrate mitochondrial problems.
Mitochondrial deficits have been found in a subgroup of
children with idiopathic autism (Giulivi et al. 2010;
Oliveira et al. 2005), but the types of defects vary. In the
premutation, the levels of the mitochondrial proteins
correlated inversely with the CGG-repeat numbers in the
premutation range. These protein changes increase oxida-
tive stress, increase oxidatively modified mitochondrial
proteins, and activate the unfolded protein response and
phosphorylation of the α subunit of the heterotrimeric
eukaryotic translational initiation factor 2 (eIF2α), resulting
in a decrease in protein translation (Ross-Inta et al. 2010).
Further studies are needed to develop effective interven-
tions for the premutation symptomatic carrier with either
neurodevelopmental or aging problems.
Conclusion
There are two ways in which the FMR1 mutation can lead
to autism or ASD. The full mutation that causes FMRP
deficiency leads to dysregulation of both GABA and
glutamate systems, which creates an imbalance of inhibito-
ry and stimulatory systems in addition to problems with
synaptic plasticity and connectivity in the brain. Many of
the proteins that are dysregulated in the absence of FMRP
are themselves associated with autism when their genes are
mutated. The premutation can lead to autism or ASD
through a process of RNA toxicity causing miRNA
dysregulation, early cell death, and mitochondrial abnor-
malities and in some cases somewhat lowered levels of
FMRP which also affect brain connectivity. It is essential to
order FMR1 DNA testing in any individual who presents
with ASD of unknown etiology. The identification of the
full mutation can lead to the use of targeted treatments, and
new interventions are currently being studied in those with
the premutation (Hagerman et al. 2008).
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